Morgan Stanley Upgrades Nurix Therapeutics to Overweight, Raises Price Target to $36

Benzinga · 5d ago
Morgan Stanley analyst Terence Flynn upgrades Nurix Therapeutics (NASDAQ:NRIX) from Equal-Weight to Overweight and raises the price target from $15 to $36.